Iron Mountain Declares Second Quarter 2017 Dividend

BOSTON--(BUSINESS WIRE)-- The Board of Directors (the “Board”) of Iron Mountain Incorporated (NYSE: IRM /ASX: INM), the storage and information management company, declared a cash dividend of USD $0.55 per share on the common stock and Chess Depository Interests (CDIs) of the company, payable to shareholders of record at the close of business on June 15, 2017.

The payable date for NYSE listed common stock holders is July 3, 2017, and the payable date for ASX listed CDIs is on July 14, 2017. CDI holders will be paid in Australian dollars, and the conversion is expected to occur on July 3, 2017.

About Iron MountainIron Mountain Incorporated (NYSE: IRM) is the global leader for storage and information management services. Trusted by more than 230,000 organizations around the world, Iron Mountain boasts a real estate network of more than 85 million square feet across more than 1,400 facilities in 47 countries dedicated to protecting and preserving what matters most for its customers. Iron Mountain’s solutions portfolio includes records management, data management, document management, data centers, art storage and logistics, and secure shredding help organizations to lower storage costs, comply with regulations, recover from disaster, and better use their information. Founded in 1951, Iron Mountain stores and protects billions of information assets, including critical business documents, electronic information, medical data and cultural and historical artifacts. Visit www.ironmountain.com for more information.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170524005875/en/

Iron Mountain
Investor Relations Contacts:
Melissa Marsden, 617-535-8595
Senior Vice President, Investor Relations
[email protected]
or
Faten Freiha, 617-535-8404
Director, Investor Relations
[email protected]

Source: Iron Mountain

You May Also Be Interested In

• BlockDAG Pulls in $2M in 24 Hours as Aptos Crypto and Zcash Seek Their Next Rally! Why Buyers Are Rushing In
• ZenaTech Anticipates Competitive Advantage for ZenaDrone as U.S. Imposes Tariffs of Up to 100% on Imported Drones and Components
• Radiopharm Theranostics To Meet with U.S. FDA to Align on Pivotal Phase 3 Trial Design for RAD 101 in Diagnosis of Brain Metastases